T Cell receptor-induced NF-kB and JNK activation
T Cell receptor-induced NF-kB and JNK activation
批准号:
8079537
负责人:
XIN LIN
金额:
$30.19万
依托单位国家:
美国
项目类别:
财政年份:
2002
资助国家:
美国
项目状态:
已结题
起止时间:
2002-08-01 至 2013-02-28
关键词:
Adaptor Signaling ProteinAntigen ReceptorsAntigen-Presenting CellsAntigensAutoimmune ProcessAutoimmunityBindingBiologicalBiological ProcessCD3 AntigensCell Differentiation processCell membraneComplexCytoplasmDDX6 geneDiseaseEventFundingGene Expression ProfileGoalsImmune responseImmunologic Deficiency SyndromesInvestigationJUN geneLinkMAPK14 geneMAPK8 geneMAPK9 geneMajor Histocompatibility ComplexMalignant NeoplasmsMediatingMembraneMolecularNF-kappa BPeptidesPhosphorylationPhosphotransferasesPlayPrincipal InvestigatorProductionProtein IsoformsProto-Oncogene Proteins c-junReceptor SignalingRecruitment ActivityResearchRoleSeriesSignal PathwaySignal TransductionSignal Transduction PathwaySurfaceT-Cell ActivationT-Cell ImmunodeficiencyT-Cell ProliferationT-Cell ReceptorT-LymphocyteTherapeutic AgentsTranscription Factor AP-1Transmembrane DomainUbiquitinationbasecytokinedesignimmunological synapseinsightleukemia/lymphomanovelnovel therapeuticsnuclear factors of activated T-cellsprogramspublic health relevancescaffoldtherapeutic targettranscription factor
中文摘要
描述(由申请人提供):T淋巴细胞(T细胞)激活在免疫应答中起关键作用。解除T细胞激活的管制将导致癌症、自身免疫或免疫缺陷疾病。T细胞活化是由抗原呈递细胞(APC)上的主要组织相容性复合体(MHC)分子诱导的,抗原呈递细胞(APC)将抗原肽呈递给T细胞表面的T细胞受体(TCR)。这种对TCR/CD3复合物的刺激诱导了一系列信号转导级联反应,导致各种激酶如IKK、JNK和p38的激活。这些活化的激酶进一步调节多种转录因子的激活,包括NF-?NF-AT和AP-1。这些转录因子最终控制T细胞中的基因表达谱,导致细胞因子的产生,以及T细胞的增殖和分化。我们实验室和其他人最近的研究表明,支架分子CARMA1在NF-?B和JNK在TCR刺激后的激活。虽然CARMA1介导tcr诱导的NF-?通过调节I?B激酶(IKK)复合物,CARMA1参与IKK活化的分子机制尚未完全确定。此外,carma1介导的JNK活化在T细胞活化和分化中的作用仍有待确定。为了研究CARMA1如何参与tcr诱导的信号转导及其在T细胞增殖和分化中的作用,在该应用中提出了四个特定目标。具体目的是:(1)确定CARMA1如何被募集到免疫突触;(2)确定介导tcr诱导的IKK激活的信号通路;(3)明确carma1介导的JNK2激活在T细胞活化和分化中的作用。这些研究不仅将揭示tcr诱导的信号通路的基本机制,还将为确定自身免疫、免疫缺陷和T细胞恶性肿瘤的未知原因提供分子视角。因此,这些研究结果将为设计治疗这些疾病的新型药物提供分子基础。公共卫生相关声明:T细胞的激活和分化在免疫反应中起着关键作用。在这项应用中,我们建议研究CARMA1及其相关信号事件在T细胞受体诱导的NF-?B和JNK的激活对T细胞的激活和分化起关键作用。这些研究结果将为设计治疗自身免疫、免疫缺陷、白血病和淋巴瘤的新药物提供分子基础。
英文摘要
DESCRIPTION (provided by applicant): T lymphocyte (T cell) activation plays a critical role in immune responses. Deregulation of T cell activation will result in cancer, autoimmune, or immunodeficiency diseases. T cell activation is induced by major-histocompatibility-complex (MHC) molecules on antigen-presenting cells (APC) presenting antigen peptides to T cell receptors (TCR) on the surface of T cells. This stimulation on TCR/CD3 complexes induces a series of signal transduction cascades leading to activation of various kinases such IKK, JNK, and p38. These activated kinases further regulate the activation of multiple transcription factors including NF-?B, NF-AT, and AP-1. These transcription factors ultimately control the gene expression profile in T cells, leading to production of cytokines, and T cell proliferation and differentiation. Recent studies from our lab and others demonstrate that CARMA1, a scaffold molecule, plays a critical role in NF-?B and JNK activation following the stimulation of TCR. Although it is clear that CARMA1 mediates TCR-induced NF-?B activation through regulating I?B kinase (IKK) complex, the molecular mechanism by which CARMA1 is involved in IKK activation is not fully defined. In addition, the role of CARMA1-mediated JNK activation in T cell activation and differentiation remains to be determined. To investigate how CARMA1 is involved in TCR-induced signal transduction and its role in T cell proliferation and differentiation, four specific aims are proposed in this application. The specific aims are: (1) to determine how CARMA1 is recruited into immunological synapse; (2) to determine the signaling pathways mediating TCR-induced IKK activation; (3) to define the role of CARMA1-mediated JNK2 activation in T cell activation and differentiation. These studies will not only reveal the basic mechanism of the TCR-induced signaling pathway, but also provide the molecular insight for determining the unknown causes of autoimmunity, immunodeficiency, and T cell malignancy. Therefore, the results from these studies will provide the molecular basis for designing novel therapeutic agents to treat these diseases. Public Health Relevance Statement: T cell activation and differentiation plays a critical role in immune responses. In this application, we propose to investigate the role of CARMA1 and its associated signaling events in T cell receptor-induced NF-?B and JNK activation that plays pivotal roles for T cell activation and differentiation. The results from these studies will provide the molecular basis for designing novel therapeutic agents to treat autoimmunity, immunodeficiency, leukemia, and lymphoma.
期刊论文(27)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
DOI:
10.1084/jem.20122327
发表时间:
2013-07-29
期刊:
The Journal of experimental medicine
影响因子:
--
作者:
[Liu X, Li H, Zhong B, Blonska M, Gorjestani S, Yan M, Tian Q, Zhang DE, Lin X, Dong C]
通讯作者:
Dong C
DOI:
10.1158/0008-5472.can-10-3626
发表时间:
2011-03-15
期刊:
Cancer research
影响因子:
11.2
作者:
[Jiang T, Grabiner B, Zhu Y, Jiang C, Li H, You Y, Lang J, Hung MC, Lin X]
通讯作者:
Lin X
DOI:
10.1111/j.1600-065x.2008.00749.x
发表时间:
2009-03
期刊:
Immunological reviews
影响因子:
8.7
作者:
[Blonska M, Lin X]
通讯作者:
Lin X
DOI:
10.1111/j.1600-065x.2012.01110.x
发表时间:
2012-03
期刊:
Immunological reviews
影响因子:
8.7
作者:
[Jiang C, Lin X]
通讯作者:
Lin X
Dampening NF-κB signaling by "self-eating".
通过“自噬”抑制 NF-κB 信号传导。
DOI:
10.1016/j.immuni.2012.06.008
发表时间:
2012
期刊:
Immunity
影响因子:
32.4
作者:
[Blonska,Marzenna, Lin,Xin]
通讯作者:
Lin,Xin
CARMA3-mediated NF-kappaB activation in GPCR signaling pathways
-
批准号:7930027
-
项目类别:
-
资助金额:$20.34万
-
财政年份:2009
-
负责人:XIN LIN
-
依托单位:
CARMA3-mediated NF-kappaB activation in GPCR signaling pathways
-
批准号:7858247
-
项目类别:
-
资助金额:$28.97万
-
财政年份:2007
-
负责人:XIN LIN
-
依托单位:
CARMA3-mediated NF-kappaB activation in GPCR signaling pathways
-
批准号:7623530
-
项目类别:
-
资助金额:$29.26万
-
财政年份:2007
-
负责人:XIN LIN
-
依托单位:
CARMA3-mediated NF-kappaB activation in GPCR signaling pathways
-
批准号:7479164
-
项目类别:
-
资助金额:$29.26万
-
财政年份:2007
-
负责人:XIN LIN
-
依托单位:
CARMA3-mediated NF-kappaB activation in GPCR signaling pathways
-
批准号:7317413
-
项目类别:
-
资助金额:$29.26万
-
财政年份:2007
-
负责人:XIN LIN
-
依托单位:
Positive and negative regulation of TNF alpha signaling
-
批准号:6900335
-
项目类别:
-
资助金额:$26.25万
-
财政年份:2002
-
负责人:XIN LIN
-
依托单位:
PKC-theta-induced NF-kB activation in T Cells
-
批准号:7105467
-
项目类别:
-
资助金额:$24.77万
-
财政年份:2002
-
负责人:XIN LIN
-
依托单位:
Positive and negative regulation of TNF alpha signaling
-
批准号:7087968
-
项目类别:
-
资助金额:$25.63万
-
财政年份:2002
-
负责人:XIN LIN
-
依托单位:
CARMA1-mediated NF-kB activation in lymphocyte activation
-
批准号:7481582
-
项目类别:
-
资助金额:$25.79万
-
财政年份:2002
-
负责人:XIN LIN
-
依托单位:
The function of CARD9 in innate immune responses
-
批准号:8284204
-
项目类别:
-
资助金额:$34.3万
-
财政年份:2002
-
负责人:XIN LIN
-
依托单位:
PKC-theta-induced NF-kB activation in T Cells
-
批准号:6507857
-
项目类别:
-
资助金额:$27.28万
-
财政年份:2002
-
负责人:XIN LIN
-
依托单位:
PKC-theta-induced NF-kB activation in T Cells
-
批准号:6612709
-
项目类别:
-
资助金额:$26.14万
-
财政年份:2002
-
负责人:XIN LIN
-
依托单位:
Positive and negative regulation of TNF alpha signaling
-
批准号:6640175
-
项目类别:
-
资助金额:$26.75万
-
财政年份:2002
-
负责人:XIN LIN
-
依托单位:
Positive and negative regulation of TNF alpha signaling
-
批准号:6759329
-
项目类别:
-
资助金额:$14.58万
-
财政年份:2002
-
负责人:XIN LIN
-
依托单位:
The function of CARD9 in innate immune responses
-
批准号:8259250
-
项目类别:
-
资助金额:$34.3万
-
财政年份:2002
-
负责人:XIN LIN
-
依托单位:
PKC-theta-induced NF-kB activation in T Cells
-
批准号:6988813
-
项目类别:
-
资助金额:$25.37万
-
财政年份:2002
-
负责人:XIN LIN
-
依托单位:
T Cell receptor-induced NF-kB and JNK activation
-
批准号:7665456
-
项目类别:
-
资助金额:$30.8万
-
财政年份:2002
-
负责人:XIN LIN
-
依托单位:
The function of CARD9 in innate immune responses
-
批准号:7849944
-
项目类别:
-
资助金额:$34.65万
-
财政年份:2002
-
负责人:XIN LIN
-
依托单位:
PKC-theta-induced NF-kB activation in T Cells
-
批准号:6929729
-
项目类别:
-
资助金额:$24.1万
-
财政年份:2002
-
负责人:XIN LIN
-
依托单位:
Positive and negative regulation of TNF alpha signaling
-
批准号:6543179
-
项目类别:
-
资助金额:$26.59万
-
财政年份:2002
-
负责人:XIN LIN
-
依托单位:
海外基金